Methylphenobarbital
From Wikipedia, the free encyclopedia
Methylphenobarbital
|
|
Systematic (IUPAC) name | |
5-phenyl-5-ethyl- 3-methylbarbituric acid |
|
Identifiers | |
CAS number | |
ATC code | N03 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C13H14N2O3 |
Mol. mass | 246.3 |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 70-76% |
Metabolism | Hepatic |
Half life | 34 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Methylphenobarbital, also known as mephobarbital, (marketed in the US under the brand name Mebaral by Ovation) is a drug which is a barbiturate derivative.
Methylphenobarbital is used as a sedative, anxiolytic and anticonvulsant. It is the N-methylated analogue of phenobarbital, and has similar indications, therapeutic value, and tolerability.
[edit] Approval History
- 1935 Mebaral was introduced by Winthrop Pharmaceuticals.
- 2001 Methylphenobarbital discontinued in the UK.
- 2003 Mebaral acquired by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).
[edit] Overdose symptoms
Symptoms of overdose of metharbital include confusion, decrease in or loss of reflexes, somnolence, pyrexia, irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness
[edit] References
- The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8
|